Novas perspectivas no tratamento medicamentoso da doença de Alzheimer: uma revisão integrativa.

Abstract

Alzheimer disease is considered a neurodegenerative disorder, leading to cognitive and neuropsychiatric alterations that may result in incapacitation. Initially, patients present with memory loss. Attention and verbal fluency deficit, as well as inability in performing calculations or even using instruments of daily living may be a result of such disorder over time. Nowadays, between 17 to 25 million people present with it worldwide. Data suggest that one out of ten people aged over 80 years may suffer from this disease, which has no cure. The treatment encompasses medication usage, specially cholinesterase inhibitors. Several studies are being conducted in order to investigate new treatments that have emerged against this disorder. Hence, this integrative literature review aims to identify new perspectives of treatment for Alzheimer disease, considering selected studies from the following databases: Latin Literature American and Caribbean Health Sciences (LILACS), Scientific Electronic Library Online (SciELO) and Medical Published – service of the US National Library of Medicine (PubMed). Inclusion criteria were: studies with abstract and full text available, published in Portugueses, English or Spanish throughout July 1st, 2013 to July 1st, 2016; sample composed by humans aged over 65 years old. The analysis identified the following new Alzheimer disease’s treatments: memantine, vitamin E, use of TTP488, use of anti TNF alpha, transcranial direct current stimulation and diuretics. Although research centers still have a lot of options to be tested, new proposals have been emerging in order to reduce the disease progression.